Dual checkpoint inhibitor-associated eosinophilic enteritis
| Autor: | Yvonne M. Saenger, Jessica Yang, Richard D. Carvajal, S. M. Lagana |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Cancer Research Skin Neoplasms Immunology Case Report Hypereosinophilia Ipilimumab Inflammation lcsh:RC254-282 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Checkpoint inhibition Eosinophilia medicine Humans Immunology and Allergy Melanoma Aged Eosinophilic enteritis Pharmacology business.industry respiratory system lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Enteritis Immune checkpoint Nivolumab 030104 developmental biology Oncology Gastritis 030220 oncology & carcinogenesis Cutaneous melanoma Prednisone Molecular Medicine medicine.symptom business medicine.drug |
| Zdroj: | Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019) Journal for Immunotherapy of Cancer |
| ISSN: | 2051-1426 |
| Popis: | Background Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events. Case presentation We report a case of dual checkpoint inhibitor-associated hypereosinophilia and eosinophilic enteritis in a patient with advanced cutaneous melanoma. Rapid resolution of peripheral eosinophilia and associated symptoms was achieved with steroids alone. Conclusions Immune checkpoint inhibition can trigger inflammation in virtually any organ in the body, leading to diverse clinical manifestations. To our knowledge, this is the first case report of eosinophilic enteritis due to ipilimumab plus nivolumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink